Ctt Pharmaceutic Financials
This page shows Ctt Pharmaceutic (CTTH) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 5 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Financial Health Signals
For every $1 of reported earnings, Ctt Pharmaceutic generates $0.11 in operating cash flow (-$72K OCF vs -$672K net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
Key Financial Metrics
Ctt Pharmaceutic reported -$672K in net income in fiscal year 2014. This represents a decrease of 3454.3% from the prior year.
Ctt Pharmaceutic held $81K in cash against $0 in long-term debt as of fiscal year 2014.
Ctt Pharmaceutic had 20M shares outstanding in fiscal year 2014. This represents an increase of 107.2% from the prior year.
CTTH Income Statement
| Metric | Q3'15 | Q2'15 | Q1'15 | Q3'14 | Q2'14 | Q1'14 | Q3'13 | Q2'13 |
|---|---|---|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Cost of Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D Expenses | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| SG&A Expenses | $15K+234.4% | $4K-87.2% | $35K+169.4% | $13K+1313.3% | $916+1.0% | $907-7.0% | $975-96.5% | $28K |
| Operating Income | N/A | N/A | -$337K | N/A | -$22K-1234.2% | -$2K+93.5% | -$26K+58.8% | -$63K |
| Interest Expense | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Income Tax | N/A | N/A | N/A | N/A | N/A | N/A | $0 | N/A |
| Net Income | -$342K+5.7% | -$363K-7.6% | -$337K-680.3% | -$43K-4595.2% | -$920+45.0% | -$2K+80.3% | -$8K+86.7% | -$64K |
| EPS (Diluted) | N/A | N/A | N/A | N/A | $0.00 | $0.00 | $0.00+100.0% | $-0.01 |
CTTH Balance Sheet
| Metric | Q3'15 | Q2'15 | Q1'15 | Q3'14 | Q2'14 | Q1'14 | Q3'13 | Q2'13 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $922K-22.1% | $1.2M-16.6% | $1.4M-14.6% | $1.7M+630.6% | $228K+1221.5% | $17K | $0-100.0% | $14K |
| Current Assets | $922K-3.8% | $959K-8.0% | $1.0M-0.7% | $1.0M | N/A | N/A | $6K | N/A |
| Cash & Equivalents | $32K-30.3% | $46K-37.3% | $73K-9.5% | $81K+2112.6% | $4K-19.3% | $5K | $0-100.0% | $8K |
| Inventory | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Accounts Receivable | $5K0.0% | $5K0.0% | $5K0.0% | $5K | N/A | N/A | N/A | N/A |
| Goodwill | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $184K+17.6% | $156K-26.1% | $212K+24.9% | $169K+19.4% | $142K-49.3% | $280K+854.5% | $29K-94.0% | $491K |
| Current Liabilities | N/A | N/A | N/A | N/A | N/A | N/A | $249K | N/A |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | $738K-28.1% | $1.0M-14.9% | $1.2M-19.1% | $1.5M+1644.9% | $86K+132.6% | -$263K-795.7% | -$29K+93.8% | -$476K |
| Retained Earnings | -$1.9M-21.8% | -$1.6M-30.1% | -$1.2M-38.9% | -$867K | N/A | N/A | -$195K | N/A |
CTTH Cash Flow Statement
| Metric | Q3'15 | Q2'15 | Q1'15 | Q3'14 | Q2'14 | Q1'14 | Q3'13 | Q2'13 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$16K+46.7% | -$29K+26.5% | -$40K+15.3% | -$47K-63.0% | -$29K-8608.2% | -$330-57.9% | -$209+99.4% | -$34K |
| Capital Expenditures | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Investing Cash Flow | N/A | N/A | N/A | -$1+100.0% | -$148K-618.0% | $29K-77.2% | $125K+448.4% | $23K |
| Financing Cash Flow | -$959-134.4% | $3K-90.2% | $29K+685.6% | -$5K-101.3% | $387K+7833.3% | $5K | $0 | $0 |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
CTTH Financial Ratios
| Metric | Q3'15 | Q2'15 | Q1'15 | Q3'14 | Q2'14 | Q1'14 | Q3'13 | Q2'13 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Equity | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Assets | -37.1%-6.4pp | -30.6%-6.9pp | -23.8%+9.3pp | -33.0%-32.6pp | -0.4%+9.3pp | -9.7%+112.6pp | -122.3%+319.6pp | -441.9% |
| Current Ratio | N/A | N/A | N/A | N/A | N/A | N/A | 0.03 | N/A |
| Debt-to-Equity | 0.25+0.1 | 0.15-0.0 | 0.18+0.1 | 0.11-1.5 | 1.66+2.7 | -1.07-0.1 | -1.00+0.0 | -1.03 |
| FCF Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Similar Companies
Frequently Asked Questions
Is Ctt Pharmaceutic profitable?
No, Ctt Pharmaceutic (CTTH) reported a net income of -$672K in fiscal year 2014.
What is Ctt Pharmaceutic's operating cash flow?
Ctt Pharmaceutic (CTTH) generated -$72K in operating cash flow during fiscal year 2014, representing cash generated from core business activities.
What are Ctt Pharmaceutic's total assets?
Ctt Pharmaceutic (CTTH) had $1.7M in total assets as of fiscal year 2014, including both current and long-term assets.
How many shares does Ctt Pharmaceutic have outstanding?
Ctt Pharmaceutic (CTTH) had 20M shares outstanding as of fiscal year 2014.
What is Ctt Pharmaceutic's debt-to-equity ratio?
Ctt Pharmaceutic (CTTH) had a debt-to-equity ratio of 0.11 as of fiscal year 2014, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Ctt Pharmaceutic's return on assets (ROA)?
Ctt Pharmaceutic (CTTH) had a return on assets of -40.4% for fiscal year 2014, measuring how efficiently the company uses its assets to generate profit.
What is Ctt Pharmaceutic's cash runway?
Based on fiscal year 2014 data, Ctt Pharmaceutic (CTTH) had $81K in cash against an annual operating cash burn of $72K. This gives an estimated cash runway of approximately 13 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
Are Ctt Pharmaceutic's earnings high quality?
Ctt Pharmaceutic (CTTH) has an earnings quality ratio of 0.11x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.